Novel therapies to prevent diabetic retinopathy.
Skolnick
A A
AA
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D003930:Diabetic Retinopathy / Q000517:prevention & control*; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D051272:Glucose Transporter Type 1; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors*; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D008222:Lymphokines / Q000037:antagonists & inhibitors; D009004:Monosaccharide Transport Proteins / Q000037:antagonists & inhibitors; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D014810:Vitamin E / Q000627:therapeutic use
D000975:Antioxidants; D016228:Endothelial Growth Factors; D004791:Enzyme Inhibitors; D051272:Glucose Transporter Type 1; D017127:Glycation End Products, Advanced; D006146:Guanidines; D008222:Lymphokines; D009004:Monosaccharide Transport Proteins; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; C495677:SLC2A1 protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D014810:Vitamin E; D011493:Protein Kinase C; C004479:pimagedine